Topline data were announced from a phase 2/3 trial evaluating immune globulin intravenous (human) in patients with post-polio syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback